Cancer Research Landon Prizes for Basic and Translational Cancer Research  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sohur, U. S.
Right arrow Articles by Kerr, L. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sohur, U. S.
Right arrow Articles by Kerr, L. D.
[Cancer Research 60, 1202-1205, March 1, 2000]
© 2000 American Association for Cancer Research


Advances in Brief

Nuclear Factor-{kappa}B/Rel Is Apoptogenic in Cytokine Withdrawal-induced Programmed Cell Death1

U. Shivraj Sohur, Chih-Li Chen, Donna J. Hicks, Fiona E. Yull and Lawrence D. Kerr2

Departments of Microbiology and Immunology [U. S. S., C-L. C., D. J. H., L. D. K.], and Cell Biology [F. E. Y., L. D. K.], and the Vanderbilt Cancer Center [L. D. K.], Vanderbilt University School of Medicine, Nashville, Tennessee 37232

In the complex microenvironment where they evolve, developing cells undergo rapid programmed cell death (PCD) when cytokines that support them become limiting. The transcriptional mechanisms of cytokine-withdrawal apoptosis are poorly understood. In this report, we used early B-lymphocyte tissue culture and transgenic cells to demonstrate that nuclear factor-{kappa}B (NF-{kappa}B) promotes apoptosis during cytokine withdrawal-induced PCD. In the progenitor B lymphocyte model FL5.12, whereas NF-{kappa}B has an antiapoptotic function in response to tumor necrosis factor-{alpha}, cytokine withdrawal causes nuclear translocation of NF-{kappa}B/cRel, where it is apoptogenic. Inhibition of NF-{kappa}B activation delays cytokine withdrawal-induced PCD in both FL5.12 and transgenic early B cells. Additionally, reconstituting a bone marrow microenvironment ex vivo abrogates the differential apoptotic pattern between control and transgenic early B cells.




This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
S. P. Tabruyn, C. M. Sorlet, F. Rentier-Delrue, V. Bours, R. I. Weiner, J. A. Martial, and I. Struman
The Antiangiogenic Factor 16K Human Prolactin Induces Caspase-Dependent Apoptosis by a Mechanism that Requires Activation of Nuclear Factor-{kappa}B
Mol. Endocrinol., September 1, 2003; 17(9): 1815 - 1823.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
B. Rayet, Y. Fan, and C. Gelinas
Mutations in the v-Rel Transactivation Domain Indicate Altered Phosphorylation and Identify a Subset of NF-{kappa}B-Regulated Cell Death Inhibitors Important for v-Rel Transforming Activity
Mol. Cell. Biol., March 1, 2003; 23(5): 1520 - 1533.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Yang and A. Richmond
Constitutive I{{kappa}}B Kinase Activity Correlates with Nuclear Factor-{{kappa}}B Activation in Human Melanoma Cells
Cancer Res., June 1, 2001; 61(12): 4901 - 4909.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.